Partnership Overview
Helix has recently partnered with Veracyte to transform how genomic insights are utilized in the treatment of prostate cancer. Their collaboration aims to streamline the integration of comprehensive germline testing for urologists and their patients, particularly for those facing high-risk localized and metastatic prostate cancer. This partnership brings crucial hereditary cancer insights closer to cancer care providers and their patients.
Innovative Approach to Cancer Testing
This partnership allows the integration of Helix's advanced whole-exome hereditary cancer test alongside Veracyte's Decipher Prostate test. This fusion of technologies offers urologists a more complete overview of the unique cancer profiles of their patients. By combining these methods, doctors can make better-informed decisions regarding treatment strategies and personalized patient care.
The Importance of Germline Testing
According to leading medical guidelines, germline genetic testing is essential for patients with metastatic and high-risk localized prostate cancer. These tests are instrumental in influencing treatment decisions, particularly with targeted therapies like PARP inhibitors. The collaboration between Helix and Veracyte ensures that physicians have convenient access to vital genetic information, enhancing the overall care their patients receive.
Quotes from Leaders in the Field
"Patients diagnosed with cancer deserve seamless access to genomic insights that can improve their care— not just in specialized centers, but wherever they are treated," said James Lu, M.D., Ph.D., CEO and co-founder of Helix. The partnership strives to broaden patient access to both germline and transcriptomic insights, allowing healthcare providers to align their treatment plans with current clinical guidelines effectively.
Benefits of Understanding Genetic Predisposition
Understanding an individual’s inherited cancer predisposition can lead to significant benefits. Not only does it help guide appropriate treatment selections, but it also identifies risks for additional cancers and provides actionable insights for family members who may be at risk. In conjunction with pharmacogenomics, such testing allows healthcare providers to match treatments more effectively to each patient's genetic makeup, thus improving the safety and efficacy of prescribed therapies.
Contributions to Precision Medicine
This collaboration aligns with Helix's larger mission to enhance the availability and effectiveness of precision medicine for all patients. Helix operates the Helix Research Network, which is recognized as the largest and most rapidly expanding precision clinical research network globally. Through this network, numerous partners have initiated universal cancer screening programs aimed at early diagnosis for cancer patients. With their proprietary Exome+ assay and Sequence Once, Query Often model, Helix continues to provide high-quality genomic insights that hold the potential to minimize the necessity for repeated testing.
Advancing Precision Oncology
To explore more about how Helix is advancing the field of precision oncology, visit their official website. They are at the forefront of population genomics and precision health, propelling the integration of genomic data into patient care and the development of therapeutic approaches.
About Helix
Helix is a pioneering organization in the realm of population genomics and precision health, facilitating health systems, life sciences firms, and payers in accelerating the application of genomic data within patient care and therapeutic innovations.
Media Contact for Helix
For further inquiries, please reach out via email to helix@highwirepr.com.
Frequently Asked Questions
What is the purpose of the Helix and Veracyte partnership?
The partnership aims to enhance access to comprehensive genetic testing for patients with prostate cancer, facilitating better treatment options.
How does germline testing impact prostate cancer treatment?
Germline testing provides crucial insights that influence treatment decisions, particularly in high-risk cancer patients, allowing for targeted therapy applications.
What innovations does Helix provide in precision medicine?
Helix is known for its Exome+ assay and a unique model that enables ongoing clinical value and potentially reduces the need for repeat testing.
Where can I find more information about Helix?
More information about Helix's work in precision oncology can be found on their official website.
How can understanding inherited cancer predisposition benefit patients?
It can guide treatment options and alert family members of potential risks, contributing to proactive health measures.
